Many of you may have seen the article in the New York Times and other news media outlets relative to the breast cancer drug tamoxifen. As many of you know, I was involved in the STAR trial which compared tamoxifen and raloxifene for breast cancer prevention. Much of my academic work has been involved in the ultrasound appearance of the uterus in patients receiving tamoxifen therapy. I’ve had a long standing interest in the treatment of estrogen receptor positive breast cancers and selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene.